Allos' antifolate PDX receives orphan-drug designation

By Elaine Rigoli

Tampa, Fla., July 26 - The Food and Drug Administration has awarded orphan-drug designation to Allos Therapeutics, Inc.'s antifolate PDX (pralatrexate) for the treatment of patients with T-cell lymphoma.

Allos said it plans to start a phase 2 study of PDX in patients with relapsed or refractory peripheral T-cell lymphoma in the third quarter of 2006.

Interim results from a phase 1/ 2 study of PDX in patients with relapsed or refractory non-Hodgkin's lymphoma and Hodgkin's disease currently ongoing at Memorial Sloan-Kettering Cancer Center demonstrated preliminary evidence of activity in patients with various subtypes of aggressive and chemotherapy resistant T-cell lymphoma, the company said in a news release.

Allos is a biopharmaceutical company located in Westminster, Colo.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.